Medimpact posted Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report Medimpact Santee, CA:

Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report

Pursuing novel mechanisms for treating cancer and validating them with clinical trials has paid off for drug developers, especially as the FDA is speeding up approvals of new treatments for unmet medical needs, a Tufts report concluded.

Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report
QR Code
Embed the QR code on your website:
Download
Copy